{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:30:49Z","timestamp":1787027449334,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"\n Background<\/jats:title>\n Enflicoxib is a COX-2 selective NSAID shown to be efficacious and safe in the treatment of pain and inflammation associated with canine osteoarthritis (OA) in clinical studies of 6 weeks duration.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This prospective, multisite, blinded, randomized, placebo-controlled, parallel-group field study aimed to confirm the safety and efficacy of enflicoxib in long-term canine OA treatments.<\/jats:p>\n <\/jats:sec>\n \n Animals<\/jats:title>\n A total of 109 client owned dogs with clinical and radiographic signs of OA for at least 3\u2009weeks were enrolled with 78 dogs completing all study visits.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Dogs were randomized at a 3:1 ratio to receive enflicoxib (\n n<\/jats:italic>\n =\u200983) or placebo (\n n<\/jats:italic>\n =\u200926) once weekly during 6 months. Dogs underwent veterinary assessments from Day 0 to Day 189 using a clinical sum score (CSS). Efficacy was also assessed by the owners using the Canine Brief Pain Inventory (CBPI). Safety was assessed clinically and by repeated blood and urine sample analysis. The efficacy outcome measure was the treatment response according to the CSS and secondarily the treatment response according to the CBPI. The primary safety outcome was the incidence of adverse events (AEs) and secondarily the evolution of the clinical pathology parameters.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Percentages of CSS responders for enflicoxib were 71.6; 74.6 and 71.6% on Days 44, 135 and 189 respectively, always showing statistically significant differences (\n p<\/jats:italic>\n &lt; 0.05) vs. placebo (41.7, 33.3, and 20.8% respectively). Treatment response according to owner assessments followed the same pattern, achieving significant differences compared to placebo after 2 weeks of treatment. The incidence and type of AEs were as described in previous enflicoxib studies of shorter duration and as for other NSAIDs, with no tendency to increase over time. No relevant changes in hematology, biochemistry or urine parameters were observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and clinical relevance<\/jats:title>\n Enflicoxib safety and efficacy profile is maintained after a long-term treatment, which together with its weekly administration, makes it a good alternative for the chronic treatment of dogs with naturally occurring OA.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fvets.2024.1349901","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T06:58:38Z","timestamp":1711090718000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A blinded, randomized and controlled multicenter field study investigating the safety and efficacy of long-term use of enflicoxib in the treatment of naturally occurring osteoarthritis in client-owned dogs"],"prefix":"10.3389","volume":"11","author":[{"given":"Josep","family":"Homedes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Ocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Riedle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Salichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fvets.2020.00220","article-title":"Risk factors for canine osteoarthritis and its predisposing arthropathies: a systematic review","volume":"7","author":"Anderson","year":"2020","journal-title":"Front Vet Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"830098","DOI":"10.3389\/fvets.2022.830098","article-title":"Proposed Canadian consensus guidelines on osteoarthritis treatment based on OA-COAST stages 1-4","volume":"9","author":"Mosley","year":"2022","journal-title":"Front Vet Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1137888","DOI":"10.3389\/fvets.2023.1137888","article-title":"COAST development Group's international consensus guidelines for the treatment of canine osteoarthritis","volume":"10","author":"Cachon","year":"2023","journal-title":"Front Vet Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jsap.13566","article-title":"2022 WSAVA guidelines for the recognition, assessment and treatment of pain","volume":"64","author":"Monteiro","year":"2022","journal-title":"J Small Anim Pract"},{"key":"ref5","year":"2021"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/tlo.08160","article-title":"COX-2 inhibition combined with radiation reduces Orthotopic glioma outgrowth by targeting the tumor vasculature","volume":"2","author":"Wagemakers","year":"2009","journal-title":"Transl Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/vms3.670","article-title":"Pharmacology of enflicoxib, a new coxib drug: efficacy and dose determination by clinical and pharmacokinetic-guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model","volume":"8","author":"Cendr\u00f3s","year":"2022","journal-title":"Vet Med Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e949","DOI":"10.1002\/vetr.949","article-title":"Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: a 6-week randomised, controlled, blind, multicentre clinical trial","volume":"191","author":"Salichs","year":"2022","journal-title":"Vet Rec"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0274800","DOI":"10.1371\/journal.pone.0274800","article-title":"Enflicoxib for canine osteoarthritis: a randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib","volume":"17","author":"Salichs","year":"2022","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/vr.c97","article-title":"Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis","volume":"166","author":"Innes","year":"2010","journal-title":"Vet Rec"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12917-021-02910-0","article-title":"Long-term safety evaluation of Daxocox\u00ae tablets (enflicoxib) in dogs after weekly oral administrations for seven months","volume":"17","author":"Homedes","year":"2021","journal-title":"BMC Vet Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/jvim.12127","article-title":"Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs","volume":"27","author":"Monteiro-Steagall","year":"2013","journal-title":"J Vet Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.cvsm.2019.07.009","article-title":"Antiinflammatory drugs","volume":"49","author":"Monteiro","year":"2019","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref14","article-title":"International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products, Good Clinical Practice, June 2000 effective 01 July 2001","year":"2000"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/vr.102397","article-title":"Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis","volume":"176","author":"Payne-Johnson","year":"2015","journal-title":"Vet Rec"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2460\/ajvr.68.6.631","article-title":"Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis","volume":"68","author":"Brown","year":"2007","journal-title":"Am J Vet Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2460\/javma.233.8.1278","article-title":"Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis","volume":"233","author":"Brown","year":"2008","journal-title":"J Am Vet Med Assoc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2460\/ajvr.74.12.1467","article-title":"Power of treatment success definitions when the canine brief pain inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis","volume":"74","author":"Brown","year":"2013","journal-title":"Am J Vet Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2460\/ajvr.75.4.353","article-title":"ERRATUM to: power of treatment success definitions when the canine brief pain inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis","volume":"75","author":"Brown","year":"2014","journal-title":"Am J Vet Res"},{"key":"ref20","article-title":"EMA\/CVMP\/PhVWP\/552\/2003 \u2013Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Recommendation on harmonising the approach to causality assessment for adverse events to veterinary medicinal products","year":"2013"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jvim.13948","article-title":"A prospective, randomized, masked, placebo-controlled multisite clinical study of Grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis","volume":"30","author":"Rausch-Derra","year":"2016","journal-title":"J Vet Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2460\/javma.241.10.1314","article-title":"Caregiver placebo effect for dogs with lameness from osteoarthritis","volume":"241","author":"Conzemius","year":"2012","journal-title":"J Am Vet Med Assoc"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1746-6148-8-185","article-title":"Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis","volume":"8","author":"Malek","year":"2012","journal-title":"BMC Vet Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3415\/VCOT-17-02-0020","article-title":"Efficacy of an oral nutraceutical for the treatment of canine osteoarthritis. A double-blind, randomized, placebo-controlled prospective clinical trial","volume":"30","author":"Scott","year":"2017","journal-title":"Vet Comp Orthop Traumatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e0149650","DOI":"10.1371\/journal.pone.0149650","article-title":"Serum biochemical phenotypes in the domestic dog","volume":"11","author":"Chang","year":"2016","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/019262339902700213","article-title":"\"have you seen this?\" nonsteroidal anti-inflammatory drug-induced renal papillary necrosis in a dog","volume":"27","author":"Silverman","year":"1999","journal-title":"Toxicol Pathol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1748-5827.2000.tb03151.x","article-title":"Effect of NSAID administration on creatinine clearance in healthy dogs undergoing anaesthesia and surgery","volume":"41","author":"Forsyth","year":"2000","journal-title":"J Small Anim Pract"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/dct-120030726","article-title":"Interspecies differences in the nephrotoxic response to cyclooxygenase inhibition","volume":"27","author":"Sellers","year":"2004","journal-title":"Drug Chem Toxicol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/01926230500222593","article-title":"Early pathophysiological features in canine renal papillary necrosis induced by nefiracetam","volume":"33","author":"Tsuchiya","year":"2005","journal-title":"Toxicol Pathol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/vr.d1456","article-title":"Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis","volume":"168","author":"Autefage","year":"2011","journal-title":"Vet Rec"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2885.2008.01043.x","article-title":"Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs","volume":"32","author":"Roberts","year":"2009","journal-title":"J Vet Pharmacol Ther"},{"key":"ref32","first-page":"119","article-title":"Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study","volume":"7","author":"Ryan","year":"2006","journal-title":"Vet Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12917-019-2110-7","article-title":"The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis","volume":"15","author":"Vijarnsorn","year":"2019","journal-title":"BMC Vet Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1748-5827.2002.tb00059.x","article-title":"Comparison of vedaprofen and meloxicam in dogs with musculoskeletal pain and inflammation","volume":"43","author":"Nell","year":"2002","journal-title":"J Small Anim Pract"},{"key":"ref35","first-page":"127","article-title":"Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions","volume":"7","author":"Hanson","year":"2006","journal-title":"Vet Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4102\/jsava.v80i3.198","article-title":"The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days","volume":"80","author":"Joubert","year":"2009","journal-title":"J S Afr Vet Assoc"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2885.2011.01297.x","article-title":"Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial","volume":"35","author":"Reymond","year":"2012","journal-title":"J Vet Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/vr.102435","article-title":"Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial","volume":"175","author":"Walton","year":"2014","journal-title":"Vet Rec"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/vr.159.17.547","article-title":"Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis","volume":"159","author":"Pollmeier","year":"2006","journal-title":"Vet Rec"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1111\/jsap.12200","article-title":"Guidelines for recognition, assessment and treatment of pain: WSAVA global pain council members and co-authors of this document","volume":"55","author":"Mathews","year":"2014","journal-title":"J Small Anim Pract"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tvjl.2018.02.017","article-title":"Face validity of a proposed tool for staging canine osteoarthritis: canine Osteo arthritis staging tool (COAST)","volume":"235","author":"Cachon","year":"2018","journal-title":"Vet J"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.2460\/javma.2000.216.1904","article-title":"Quality of life in animals","volume":"216","author":"McMillan","year":"2000","journal-title":"J Am Vet Med Assoc"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1349901\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T06:58:50Z","timestamp":1711090730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1349901\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":42,"alternative-id":["10.3389\/fvets.2024.1349901"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2024.1349901","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"article-number":"1349901"}}